title: Magnetic functionalised carbon nanotubes as drug vehicles for cancer lymph node metastasis treatment.
abstract: Strategies using carbon-based nanomaterials as carriers for delivering chemotherapeutic drugs to cancers have been described well. Here a novel magnetic lymphatic-targeting drug-delivery system, based on functionalised carbon nanotubes (fCNTs), is presented with the aim of improving the outcome of cancer with lymph node involvement. The potential therapeutic effect of gemcitabine (GEM) loading magnetic multiwalled carbon nanotubes (mMWNTs) was compared with that of GEM loading magnetic-activated carbon particles (mACs) in vitro and in vivo. mMWNTs-GEM and mACs-GEM both had high anti-tumour activity in vitro similar to free drug. Subcutaneous administration of GEM loading magnetic nanoparticles resulted in successful regression and inhibition of lymph node metastasis under the magnetic field, with mMWNTs-GEM superior to mACs-GEM, and more effectively in the high-dose versus low-dose groups. The successful application of intra-lymphatic delivery of chemotherapeutics using mMWNTs highlights the clinical potential of fCNTs for future cancer metastasis treatment with high efficacy and minimum side-effects.
authors.affiliation: Pancreatic Disease Institute, Department of Pancreatic Surgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Yang
authors.forename: Chen
authors.initials: C
authors.lastname: Jin
authors.forename: Dong
authors.initials: D
authors.lastname: Yang
authors.forename: Yongjian
authors.initials: Y
authors.lastname: Jiang
authors.forename: Ji
authors.initials: J
authors.lastname: Li
authors.forename: Yang
authors.initials: Y
authors.lastname: Di
authors.forename: Jianhua
authors.initials: J
authors.lastname: Hu
authors.forename: Changchun
authors.initials: C
authors.lastname: Wang
authors.forename: Quanxing
authors.initials: Q
authors.lastname: Ni
authors.forename: Deliang
authors.initials: D
authors.lastname: Fu
mesh_terms: D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000494:pharmacology; D017209:Apoptosis; D014408:Biomarkers, Tumor / Q000032:analysis*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D004195:Disease Models, Animal; D004337:Drug Carriers; D006801:Humans; D007150:Immunohistochemistry; D020287:In Situ Nick-End Labeling; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis; D058185:Magnetite Nanoparticles; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D046529:Microscopy, Electron, Transmission; D037742:Nanotubes, Carbon; D009336:Necrosis; D010190:Pancreatic Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology*; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D014408:Biomarkers, Tumor; D004337:Drug Carriers; D058185:Magnetite Nanoparticles; D037742:Nanotubes, Carbon; D003841:Deoxycytidine; D000093542:Gemcitabine